Fadi Saba, MD
Internal Medicine · St Petersburg, FLNPI 1588658348
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.5%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by AstraZeneca at 30.2% of the total. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 477 payments — averaging $58.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- Merz North America, Inc.$5K
- Astellas Pharma US Inc$4K
- Bayer$3K
- AbbVie$1K
- Pfizer$450
- plus $6K from 54 others
Across 194 payments — averaging $10,770 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$508K
- Scpharmaceuticals Inc.$365K
- Boehringer Ingelheim$270K
- AstraZeneca$213K
- Eli Lilly$187K
- Kowa Research Institute, Inc.$95K
- plus $451K from 16 others
What the payments were for
- Consulting fees$2,6109%
- Speaking & faculty fees$10,70038%
- Travel & lodging$2671%
- Food & beverage$14,47452%
- Education$430%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,094 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,858 | $706,607 |
| XifaxanRifaximin | 145 | $213,781 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 51 | $210,456 |
| OzempicSemaglutide | 166 | $206,238 |
| JanuviaSitagliptin Phosphate | 259 | $165,907 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 206 | $149,448 |
| FarxigaDapagliflozin Propanediol | 269 | $148,675 |
| TrulicityDulaglutide | 195 | $133,057 |
| XareltoRivaroxaban | 335 | $129,460 |
| JardianceEmpagliflozin | 211 | $116,541 |
| MounjaroTirzepatide | 70 | $67,427 |
| CopaxoneGlatiramer Acetate | 11 | $66,998 |
| Austedo XrDeutetrabenazine | 13 | $66,136 |
| TivicayDolutegravir Sodium | 27 | $65,715 |
| Breo ElliptaFluticasone/Vilanterol | 136 | $64,698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $450 | $706,6071,858 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp | $332 | $280,118286 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $366 | $235,342401 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $272 | $213,781145 claims |
| GileadBiktarvy | $142 | $210,45651 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $29 | $200,484265 claims |
| AstraZenecaFarxiga, Symbicort | $8,488 | $186,824402 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $209 | $171,828301 claims |
| MerckJanuvia | $106 | $165,907259 claims |
| Johnson & JohnsonXarelto, Risperdal Consta | $145 | $154,204354 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone, Austedo Xr | $299 | $133,13524 claims |
| AbbVieLinzess, Vraylar, Creon | $1,134 | $126,682141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in St Petersburg
- Donald ThomasSt Petersburg$100K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.